MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$1,883K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sale of common sto...
Stock-based compensation
Prepaid expenses and other curre...
Others
Negative Cash Flow Breakdown
Accrued expenses and other curre...
Receivables
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net (loss) income
-3,054
-7,107
-7,443
-3,962
Change in fair value of warrant liability
-215
159
89
3
Depreciation and amortization
44
44
44
15
Stock-based compensation
816
634
327
135
Receivables
1,767
-2,107
1,803
668
Prepaid expenses and other current assets
-292
480
-849
248
Other assets
0
-5
-
-
Accounts payable
-1,478
2,012
2,469
524
Accrued expenses and other current liabilities
-2,142
50
2,711
189
Deferred revenue
-
-
-1
1
Net cash used in operating activities
-7,504
-2,576
-2,758
-4,011
Cash paid for acquisition, net of cash acquired
-
-
0
2,585
Net cash used in investing activities
-
-
0
-2,585
Proceeds from sale of common stock pursuant to the atm
120
1,897
2,087
116
Proceeds from sale of common stock pursuant to the april offering
10,000
-
-
-
Payment of offering costs
730
-
1,939
178
Proceeds from exercised prefunded warrants
-
-
10
0
Net cash provided by financing activities
9,390
1,897
158
-62
Effect of foreign currency translation on cash
-3
-8
0
-3
Net increase (decrease) in cash and cash equivalents
1,883
-687
-2,600
-6,661
Cash and cash equivalents at beginning of period
3,133
3,820
6,420
21,338
Cash and cash equivalents at end of period
5,016
3,133
3,820
6,420
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
common stock pursuant...
$10,000K
Proceeds from sale of
common stock pursuant...
$120K
(-96.45%↓ Y/Y)
Net cash provided by
financing activities
$9,390K
(202.12%↑ Y/Y)
Canceled cashflow
$730K
Net increase
(decrease) in cash and cash...
$1,883K
(122.80%↑ Y/Y)
Canceled cashflow
$7,507K
Payment of offering
costs
$730K
(154.36%↑ Y/Y)
Stock-based compensation
$816K
(206.77%↑ Y/Y)
Prepaid expenses and
other current assets
-$292K
(66.89%↑ Y/Y)
Depreciation and
amortization
$44K
(2100.00%↑ Y/Y)
Net cash used in
operating activities
-$7,504K
(34.27%↑ Y/Y)
Effect of foreign
currency translation on...
-$3K
(-105.88%↓ Y/Y)
Canceled cashflow
$1,152K
Net (loss) income
-$3,054K
(-114.84%↓ Y/Y)
Accrued expenses and
other current...
-$2,142K
(-305.68%↓ Y/Y)
Receivables
$1,767K
(499.77%↑ Y/Y)
Accounts payable
-$1,478K
(59.00%↑ Y/Y)
Change in fair value of
warrant liability
-$215K
(99.19%↑ Y/Y)
Buy us a coffee
Traws Pharma, Inc. (TRAW)
Traws Pharma, Inc. (TRAW)